Zonisamide Versus Topiramate in Migraine - Trial NCT06347497
Access comprehensive clinical trial information for NCT06347497 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Migraine. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kafrelsheikh University
Timeline & Enrollment
Phase 3
Apr 01, 2024
May 01, 2025
Primary Outcome
The change in migraine days per 28 days
Summary
Investigators aim to compare the effect of zonisamide versus topiramate in migraine by
 assessing the absolute reduction in MMD in each group, the percentage of patients who
 achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline
 frequency
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06347497
Non-Device Trial